NICE initial rejection of Cinqaero (reslizumab) from Teva as an add on treatment for severe eosinophilic asthma.

The National Institute for Health and Care Excellence (NICE) is " not minded " to recommend Cinqaero (reslizumab) from Teva as an add-on to standard therapy for treating severe eosinophilic asthma inadequately controlled despite highdose inhaled corticosteroids plus another medicinal product for maintenance treatment in adults.

The committee recommends that NICE requests further clarification and an updated cost effectiveness analysis from the company, which should be made available for the second appraisal committee meeting and include: ? the effect of reslizumab on exacerbations for subgroups of people with 3 or more or with 4 or more exacerbations in the previous year. These should not include an adjustment for a placebo effect. Any adjustment related to specific subgroups should be fully explained and justified ? appropriate administration costs, including the need to go to hospital for cannula insertion and supervised infusion ? drug wastage using only the licensed 100-mg vial ? evaluation of response to treatment at periods that reflect clinical practice (such as 6 months from the start of treatment).